Quick Answer
Celldex Therapeutics, Inc. reported Total Revenue of $1.54 million for fiscal year 2025.
Celldex Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.54M -78.0% |
$7.02M +2.0% |
$6.88M +192.0% |
$2.36M -49.3% |
$4.65M -37.3% |
$7.42M +107.6% |
| Revenue (ASC 606) | $1.54M -78.0% |
$7.02M +2.0% |
$6.88M +192.0% |
$2.36M -49.3% |
$4.65M -37.3% |
$7.42M +107.6% |
| Net Income | -$258.76M -63.9% |
-$157.86M -11.6% |
-$141.43M | — | — | — |
| Diluted EPS | -$3.90 -59.2% |
-$2.45 +16.1% |
-$2.92 -21.7% |
-$2.40 -46.3% |
-$1.64 +18.8% |
-$2.02 +42.5% |
| Total Assets | $582.98M -26.4% |
$792.34M +70.2% |
$465.63M +32.0% |
$352.74M -20.7% |
$444.65M +88.5% |
$235.84M +91.8% |
| Cash and Equivalents | $28.87M +1.8% |
$28.36M -18.6% |
$34.81M +18.3% |
$29.43M -24.8% |
$39.14M -10.7% |
$43.84M +290.3% |
| Stockholders Equity | $527.16M -29.4% |
$747.00M +74.1% |
$429.17M +31.6% |
$326.20M -22.2% |
$419.48M +100.4% |
$209.36M +122.7% |
| R&D Expense | $245.07M +49.8% |
$163.55M +38.6% |
$118.01M +43.5% |
$82.26M +54.3% |
$53.31M +25.3% |
$42.53M -0.3% |
| Operating Income | -$287.37M -47.3% |
-$195.08M -26.2% |
-$154.54M -34.1% |
-$115.23M -61.7% |
-$71.24M -12.5% |
-$63.35M -15.1% |
| Shares Outstanding | 66.55M +0.3% |
66.37M +18.8% |
55.88M +18.4% |
47.20M +1.0% |
46.73M +18.0% |
39.60M +133.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $730.0K | -70.8% | +5.0% |
| Revenue (ASC 606) | June 30, 2025 | $730.0K | -70.8% | +5.0% |
| Net Income | September 30, 2025 | -$67.04M | -59.2% | -18.5% |
| Diluted EPS | September 30, 2025 | -$1.01 | -57.8% | -18.8% |
| Total Assets | September 30, 2025 | $648.44M | -21.2% | -6.4% |
| Cash and Equivalents | September 30, 2025 | $36.04M | -1.0% | +56.4% |
| Stockholders Equity | September 30, 2025 | $598.36M | -23.9% | -8.7% |
| R&D Expense | September 30, 2025 | $62.93M | +39.0% | +16.1% |
| Operating Income | September 30, 2025 | -$73.62M | -41.2% | -15.3% |
| Shares Outstanding | September 30, 2025 | 66.45M | +0.2% | +0.1% |
- Celldex Therapeutics, Inc. reported Total Revenue of $1.54 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed a decrease of -78.0% in Total Revenue compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Revenue (ASC 606) of $1.54 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed a decrease of -78.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Net Income of -$258.76 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed a decrease of -63.9% in Net Income compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Diluted EPS of $3.90 per share (loss) for fiscal year 2025.
- Celldex Therapeutics, Inc. showed a decrease of -59.2% in Diluted EPS compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Total Assets of $582.98 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed a decrease of -26.4% in Total Assets compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Cash and Equivalents of $28.87 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed an increase of +1.8% in Cash and Equivalents compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Stockholders Equity of $527.16 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed a decrease of -29.4% in Stockholders Equity compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported R&D Expense of $245.07 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed an increase of +49.8% in R&D Expense compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Operating Income of -$287.37 million for fiscal year 2025.
- Celldex Therapeutics, Inc. showed a decrease of -47.3% in Operating Income compared to the prior fiscal year.
- Celldex Therapeutics, Inc. reported Shares Outstanding of 66.55 million shares for fiscal year 2025.
- Celldex Therapeutics, Inc. showed an increase of +0.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: